NCT05442515

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2022-12-28Est. Completion: 2027-07-01

Enrollment target: 130 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

NCI Ped LeukemiaLymph Cell Tx Tmncilltct@mail.nih.gov (240) 760-6970

Sara K Silbert, M.D.sara.silbert@nih.gov (240) 760-6970

Other microbiome trials you might be interested in

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPhase 1Recruiting

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin …

Duarte, United StatesEst. completion Jun 30, 2027

View Trial →

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPhase 1Recruiting

Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma (DLBCL)

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.